[Therapy of degenerative maculopathy with Cosaldon A + E].
Results of long-term treatment with Cosaldon A + E in 173 patients (= 345 eyes) exhibiting various stages of degenerative maculopathy are presented (5 tables and 4 figures). Depending on the initial status up to 80% of the treated eyes responded positively to this therapy with only a small side-effect rate: these results suggest that Cosaldon A + E is a promising alternative in the treatment of degenerative maculopathy.
D000368:Aged; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008134:Long-Term Care; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014792:Visual Acuity / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects; D014801:Vitamin A / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*
D004338:Drug Combinations; D009539:Nicotinic Acids; D014801:Vitamin A; D014810:Vitamin E; C025790:vitamin A, pentifyllin, nicotinic acid, and vitamin E combination; D013805:Theobromine
Zur Therapie der degenerativen Makulopathie mit Cosaldon A + E.